Ensuring medication ingestion without altering existing medication regimen

确保药物摄入而不改变现有的药物治疗方案

• 批准号: 10384824
• 负责人: Tony Chris Carnes
• 金额: $ 49.64万
• 依托单位: ETECTRX, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-15 至 2023-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10384824
• 关键词: Accidents; Address; Adherence; Age; Alzheimer' s Disease; Assisted Living Facilities; Bulla; COVID-19 pandemic; Caregivers; Caring; Chronic Disease; Communication; Data; Dementia; Detection; Development; Disease Management; Dose; Drug Prescriptions; Early Intervention; Elderly; Encapsulated; Ensure; Environment; Event; Feedback; Frequencies; Galantamine; Generations; Grant; Health care facility; Hearing; Home; Impaired cognition; Individual; Ingestion; Intervention; Interview; Long-Term Care; Monitor; Neck; Network-based; Nursing Homes; Participant; Patients; Persons; Pharmaceutical Preparations; Phase; Radio; Reader; Regimen; Reporting; Retirement; Signal Transduction; Small Business Innovation Research Grant; Stomach; Structure; Symptoms; System; Technology; Time; aging population; base; capsule; care costs; care providers; cloud based; cost; design; donepezil; effectiveness evaluation; experience; improved; medication compliance; memory care; mobile application; monitoring device; pill; prototype; radio frequency; remote monitoring; repository; rivastigmine; sensor; signal processing; usability

PROJECT SUMMARY In the US, approximately 835,000 persons are living in assisted living facilities with more than 50 percent of those having some form of dementia or cognitive impairment. The average cost of those living in assisted living facilities is $4050 per month, with memory care increasing this cost by an average of $1250 per month. Advancements in medications such as Donepezil, Galantamine, and Rivastigmine have been shown to help manage and even reverse some dementia symptoms, but these medications are not effective unless they are taken on a regular basis. Slowing the progression of dementia can prolong the ability of persons to live independently. While the use of blister packs and pill boxes are designed to help ensure that patients are taking medications on a prescribed basis, these technologies report intent to ingest and often do not provide any feedback that can be monitored by others outside the home. Given that 53 million US citizens are already past retirement age and that 70 percent will require some form of long-term care in their lifetime, it is clear that the cost of managing this disease will continue to grow unless alternative solutions are put in place. In Phase I of the grant we propose to enhance the FDA cleared ID-Cap system by building a home-based ingestion monitoring system that can detect medication ingestions within the home instead of requiring a user to wear an ID-Cap Reader. The ID-Cap system is currently designed to detect ingestions by sending out a small radio signal from within a person's stomach when an ID-Cap is ingested. The existing system detects these signals using a lanyard-style reader. As these patients may forget to use the reader, we propose to create a new reader design that can “hear” the ingestion from across the room using improvements in antenna design and signal processing. To ensure detection if a patient takes their medication in different rooms, a mesh network of readers placed in the home can ensure that the signal is detected and forwarded to the existing cloud-based monitoring platform. In Phase I, we propose two specific aims. Aim 1 – Create a prototype wall-plug based networked reader Leveraging our experience developing the existing ID-Cap wearable reader, we will design a new generation reader that will be able to detect ingestions within a room instead of requiring the user to wear a reader. The captured signals will be forwarded across a mesh network to a base station that ensures delivery to a cloud repository so that care providers can monitor actual ingestion events and intervene if needed. Aim 2 – Evaluate effectiveness and acceptability of the new system in 3 simulated environments Using the prototyped base station and networked readers, we will evaluate the ability to detect signals in three different home configurations. This feedback will help inform installation configuration designs regarding the optimal number and placement of readers. Interviews with persons with dementia and their caregivers will inform acceptability.

项目摘要 在美国，大约有835,000人住在超过50％的辅助生活设施中 那些具有某种形式的痴呆或认知障碍的人。居住在辅助的人的平均成本 生活设施为每月4050美元，记忆护理平均每月增加1250美元。 多奈哌齐，甘坦明和瑞瓦斯汀等药物的进步已被证明可以帮助 管理甚至扭转了某些痴呆症症状，但是这些药物无效，除非它们是 定期服用。减慢痴呆症的进展可以延长人们的生活能力 独立。虽然使用水泡包装和药丸盒，以帮助确保患者服用 这些技术在规定的基础上报告意图摄入，并且通常不提供任何 可以由家中其他人监视的反馈。鉴于5300万美国公民已经过去了 退休年龄和70％的人将需要某种形式的长期护理，很明显 除非采用其他解决方案，否则管理这种疾病的成本将继续增长。 在赠款的第一阶段，我们提议通过建立一个家庭基础来增强FDA清除的ID-CAP系统 摄入的监测系统可以检测到家庭中的药物摄入，而不是要求用户 佩戴ID量读取器。 ID-CAP系统目前旨在通过发送小的来检测摄入 摄入ID-CAP时，从一个人的摊位中的无线电信号。现有系统检测到这些 使用挂绳式阅读器的信号。由于这些患者可能会忘记使用读者，因此我们建议创建一个 可以通过天线设计改进从整个房间“听到”整个房间摄入的新读者设计 和信号处理。为了确保患者是否在不同的房间中服用药物，网状网络 放置在家里的读者可以确保检测并转发到现有的基于云的信号 监视平台。在第一阶段，我们提出了两个具体目标。 AIM 1 - 创建基于壁插入的原型网络读者 利用我们开发现有的ID-CAP可穿戴式阅读器的经验，我们将设计新一代 读者将能够检测房间内的摄入量，而不是要求用户佩戴读者。 捕获的信号将通过网格网络转发到基站，以确保交付到云 存储库，以便护理提供者可以监视实际的摄入事件并在需要时进行干预。 目标2 - 评估3个模拟环境中新系统的有效性和可接受性 使用原型基站和网络读者，我们将评估在三个中检测信号的能力 不同的家庭配置。此反馈将有助于告知有关安装配置设计 读者的最佳数字和位置。与痴呆症患者及其护理人员的访谈将告知 可接受性。